ClinicalTrials.gg
CompletedNCT02055287LY03004SADUpdated Nov 10, 2014

Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder

A Phase 1 interventional study of LY03004 in Schizophrenia and Schizoaffective Disorder, sponsored by Luye Pharma Group Ltd.. Completed at 2 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-10.

Sponsored by Luye Pharma Group Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
97th of 123
36 · median 100
Started
2013
with 4 others
Phase 1
12 of 127
none open now
Registered
89th of 127
by date
Lead sponsor
3 of 127
Luye Pharma Group Ltd.

Among the 127 studies testing risperidone in Schizophrenia, this one is the 97th largest by enrollment of the 123 interventional ones that give a count, is one of 5 that started in 2013, is one of 12 in phase 1, and was the 89th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the safety and tolerability and preliminary efficacy of LY03004 following intramuscular injection.

03

Conditions studied

  • Schizophrenia
  • Schizoaffective Disorder

Keywords

  • schizophrenia
  • schizoaffective disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 18 to 65 years old;
  2. Patients must have a diagnosis of schizophrenia or schizoaffective disorder based on the Mini-International Neuropsychiatric Interview (MINI);
  3. Patients must be clinically stable on antipsychotic medications other than risperidone or paliperidone or clozapine for at least 4 weeks prior to screening, based on clinical assessments and a Positive and Negative Syndrome Scale (PANSS) total score less than or equal to 70 at screening visit;
  4. Patients with a in range of 18.0 to 35.0;
  5. Patients with an form signed by the patient or legally acceptable representative

Exclusion criteria

Exclusion Criteria:

  1. Patients with a mental disorders other than schizophrenia or schizoaffective disorder, according to the ;
  2. Patients who received oral risperidone or paliperidone or clozapine within 14 days prior to screening, or Risperdal Consta within 100 days prior to screening or paliperidone palmitate within 10 months prior to screening;
  3. Patients with neuroleptic malignant syndrome or physical fatigue associated with dehydration or malnutrition;
  4. Patients who pose a significant risk of a suicide attempt based on history, investigator's judgment or have answered "yes" on the questions 4 or 5 for current or past 30 days on the screening form of the Columbia Suicide Severity Rating Scale (C-SSRS).
  5. Patients with a history of sensitivity to akathisia and other EPS, especially with previous use of risperidone or paliperidone.
  6. Patients with uncontrolled diabetes mellitus as indicated by a level greater than or equal to 7%;
  7. Patients with a history of or currently having epilepsy or convulsion disorders;
  8. Patients who have had electroconvulsive therapy within the past 2 months prior to screening;
  9. Patients who used medication known to be an inducer or inhibitor for CYP 2D6 less than 2 weeks prior to screening;
  10. Patients with a history of allergic reaction to risperidone or to the of LY03004;
  11. Patients who have met DSM-IV-TR criteria for substance abuse or dependence with the exception of caffeine or nicotine in the past 6 months prior to screening
  12. Patients with a history of cardiac arrhythmia's, cardiovascular disease, thyrotoxicosis, parkinsonism, or hemorrhagic diathesis;
  13. Patients who are currently taking medications with primarily CNS activities such as antidepressants, mood stabilizers or anticonvulsants;
  14. Patients who have participated in a clinical trial of another drug within 30 days prior to screening;
  15. Female patients who are pregnant or are breastfeeding or are of without adequate .
  16. Patients who have any clinically relevant hepatic, renal and cardiac dysfunction, or other medical condition or laboratory abnormality, which in the judgment of the investigator would interfere with the subject's ability to participate in the study
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    LY03004- 12.5

    LY03004 dosage strength at 12.5mg

    Drug: LY03004

  • Experimental
    LY03004 - 25

    LY03004 Dose Strength 25mg

    Drug: LY03004

  • Experimental
    LY03004- 37.5

    LY03004 Dose Strength 37.5mg

    Drug: LY03004

  • Experimental
    LY03004 - 50

    LY03004 Dose Strength 50mg

    Drug: LY03004

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax for the Pharmacokinetics (PK) of LY03004

    Time frame: 43 Days

Secondary outcomes

  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability

    Time frame: 43 Days

  2. The change of the PANSS score for the Preliminary efficacy of LY03004

    Time frame: 43 Days

07

Study locations

2 sites
  • Neuropsychiatric Research Center of Orange County
    Orange, California 92868, United States
  • Community Clinical Research Inc
    Austin, Texas 78754, United States
08

References and documents

Publications

  • Wang W, Wang X, Dong Y, Walling DP, Liu P, Liu W, Shi Y, Sun K. Population Pharmacokinetic Analysis to Support and Facilitate Switching from Risperidone Formulations to Rykindo in Patients with Schizophrenia. Neurol Ther. 2024 Apr;13(2):355-372. doi: 10.1007/s40120-024-00578-w. Epub 2024 Jan 20. PubMed 38244179 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2013, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2014
First posted
Feb 5, 2014
Start
Mar 2013
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Nov 10, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 10, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02055287
Responsible party
Sponsor
First posted
Feb 5, 2014
Start date
Mar 2013
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Nov 10, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion